New Methods for Early Cancer Detection Discovered

Researchers at Johns Hopkins University have unveiled advanced techniques aimed at cancer detection. A study featured in the journal Cancer Discovery, which received partial funding from the National Institutes of Health, reveals that genetic material from tumors can be found in the bloodstream up to three years before a formal cancer diagnosis.

The team examined plasma samples from the large-scale Atherosclerosis Risk in Communities (ARIC) study, primarily intended to analyze risk factors associated with heart disease, strokes, and other cardiovascular conditions.

FDA Approves AI Tools for Breast Cancer Risk Prediction

Out of 52 participants, 8 showed a strong response to the Multicancer Early Detection (MCED) test, with diagnoses occurring within four months of sample collection. This type of testing is still experimental and aims to identify various types of cancer simultaneously, often detecting fragments of DNA, RNA, or proteins from abnormal cells.

Interestingly, the researchers could evaluate additional samples from six of those eight individuals, which were collected 3.1 to 3.5 years prior. In four of those samples, tumor-derived mutations were identified.

Yuxuan Wang, MD, PhD, the lead author of the study, expressed surprise at the findings. She noted that the ability to intervene much sooner could potentially reduce tumor development and improve chances of achieving a cure.

Clayton Bert Wogelstein, MD, a professor of oncology at Johns Hopkins, added that the study establishes a benchmark for effective cancer detection, suggesting that the promise of MCED testing could lead to earlier management and better outcomes.

Detecting cancer years before it typically shows up clinically could lead to more favorable treatment results. However, he also remarked on the importance of deciding on the right clinical follow-up after a positive test.